Routine ketorolac at oocyte retrieval decreases postoperative narcotic use by more than 50%

Featured Article

Like Comment
Related Content

VOLUME 2, ISSUE 2, P156-160, JUNE 01, 2021

Authors:

Emily A. Seidler, M.D., Denis A. Vaughan, M.D., Angela Q. Leung, M.D., Denny Sakkas, Ph.D., David A. Ryley, M.D., Alan S. Penzias, M.D.

Abstract:

Objective

To study the impact of routine ketorolac administration during oocyte retrieval on the proportion of patients who require postoperative narcotics for analgesia.


Design

Retrospective cohort study.


Setting

Single, university-affiliated infertility clinic.


Patient(s)

All women undergoing oocyte retrieval between July and November 2016 (non-ketorolac group [NKG]; n = 826) and April-August 2017 (ketorolac group, KG; n = 1780).


Intervention(s)

A single 30 mg intravenous dose of ketorolac was administered after the oocyte retrieval procedure.


Main outcome measure(s)

The number of patients who required postoperative narcotic analgesia, postoperative complication rate, and fresh embryo transfer pregnancy outcomes were examined.


Result(s)

In the KG, we found a significant decrease in the patients who required narcotics after oocyte retrieval compared with the NKG (12% KG vs. 25.5% NKG). We found no significant change in the clinical pregnancy rate (CPR) resulting from fresh embryo transfer after our intervention (NKG CPR 32.6%, KG CPR 32.4%). Furthermore, there was no increase in postoperative bleeding complications in the KG.


Conclusion(s)

Routine use of ketorolac at the time of oocyte retrieval may decrease the rate of postoperative opioid use without adversely impacting pregnancy and complication rates.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.